Three major trials— FOURIER, SPIRE‐1 and SPIRE‐2, and the ODYSSEY Outcomes trial—have provided significant evidence for the use of PCSK9 inhibitors in managing cardiovascular diseases (Figure 4). This evidence concerns the gene PCSK9 and cardiovascular disorder.